In the past week, CRNX stock has gone down by -29.45%, with a monthly decline of -40.78% and a quarterly plunge of -32.97%. The volatility ratio for the week is 8.93%, and the volatility levels for the last 30 days are 5.54% for Crinetics Pharmaceuticals Inc The simple moving average for the last 20 days is -29.18% for CRNX’s stock, with a simple moving average of -30.20% for the last 200 days.
Is It Worth Investing in Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Right Now?
The 36-month beta value for CRNX is at 0.62. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CRNX is 86.88M, and currently, shorts hold a 7.96% of that float. The average trading volume for CRNX on January 15, 2025 was 730.84K shares.
CRNX) stock’s latest price update
The stock of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has decreased by -8.62 when compared to last closing price of 38.98.Despite this, the company has seen a loss of -29.45% in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Citigroup repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Citigroup is $68 based on the research report published on March 06, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRNX reach a price target of $50. The rating they have provided for CRNX stocks is “Overweight” according to the report published on January 16th, 2024.
Jefferies gave a rating of “Hold” to CRNX, setting the target price at $35 in the report published on December 21st of the previous year.
CRNX Trading at -34.71% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.04% of loss for the given period.
Volatility was left at 5.54%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -35.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.12% lower at present.
During the last 5 trading sessions, CRNX fell by -29.45%, which changed the moving average for the period of 200-days by -19.83% in comparison to the 20-day moving average, which settled at $50.29. In addition, Crinetics Pharmaceuticals Inc saw -30.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Pizzuti Dana, who sale 15,000 shares at the price of $52.09 back on Jan 03 ’25. After this action, Pizzuti Dana now owns 29,248 shares of Crinetics Pharmaceuticals Inc, valued at $781,350 using the latest closing price.
DANA J PIZZUTI, the Officer of Crinetics Pharmaceuticals Inc, proposed sale 15,000 shares at $52.09 during a trade that took place back on Jan 03 ’25, which means that DANA J PIZZUTI is holding shares at $781,323 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -295.87 for the present operating margin
- -0.43 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -267.48. The total capital return value is set at -0.35. Equity return is now at value -40.26, with -35.20 for asset returns.
Based on Crinetics Pharmaceuticals Inc (CRNX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -3.8.
Currently, EBITDA for the company is -221.51 million with net debt to EBITDA at 0.87. When we switch over and look at the enterprise to sales, we see a ratio of 2924.53. The receivables turnover for the company is 0.15for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.38.
Conclusion
In conclusion, Crinetics Pharmaceuticals Inc (CRNX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
